Biogen Anti-LINGO MS Study Failure Removes Upside
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Merck & Co. Pauses Enrollment Of Oral Islatravir In PrEP Studies As Bad News Mounts
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup
Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.